Screening of key modulatory genes by Degalactotigonin in Triple Negative Breast Cancer cells – An in silico approach

• Published in: Meta Gene Vol. 26; p. 100799
• Main Authors: D, Hamsa, K, Praveen Kumar, P, Shanmughavel, A, Poornima, S, Sumathi
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.2020
• Subjects: Degalactotigonin; Down-regulated and docking studies; In silico; Micro array; Up-regulated; Up-regulated; In silico; Down-regulated and docking studies; Micro array; Degalactotigonin
• ISSN: 2214-5400; 2214-5400
• DOI: 10.1016/j.mgene.2020.100799

Breast cancer is one of the world’'s most prevalent malignant tumors among women. This is currently classified according to the expression of the receptor. Triple Negative Breast Cancer (TNBC) results poorly because of the lack of therapeutic targets. A challenge for researchers is to control effective and safer chemotherapeutic agents that target specific biochemical processes involved in cancer growth. New drug development in cancer research is one of the leading fields that have concentrated on the synthesis of new therapeutic agents that specifically target particular core cancer progression molecules. Therefore we focused on the compound Degalactotigonin in Triple Negative Breast Cancer cells in silico studies. The online software Gene Expression Omnibus (GEO) database helps to analyze the microarray datasets and identify key modulatory genes by comparing TNBC and Non-TNBC cells. In this current study, we collected three microarray data sets using GEO online tool. The integrated analyzes were conducted using three datasets namely GSE65194, GSE61724 and GSE38959 has 209 TNBC patient samples and 42 Non – TNBC patient samples. Evaluations of three data sets (9 down-regulated genes and 22 up-regulated genes in TNBC cells) were found to be expressed differently. The scrutinized genes were docked; some valuable evidence for the forthcoming design of more efficient inhibitors was provided in the docking results. This research result will provide enhanced understandings of Triple Negative Breast Cancer's carcinogenesis and can contribute to the production of molecular targets as a treatment for TNBC patients.